Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Dimitrios Stefanoudakis(APLA Health), Konstantinos G. Toutouzas(Hippocration General Hospital), Nikolaos V. Michalopoulos(National and Kapodistrian University of Athens), Alexandra Drakaki(University of California, Los Angeles), Dimitriοs Schizas(Laiko General Hospital of Athens), Maximos Frountzas(Royal Marsden NHS Foundation Trust)
Cited by 78
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411